Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
ln Vitro |
Mito-LND inhibits the invasion, migration, and development of lung cancer. H2030BrM3 and A549 cells' proliferation is inhibited by mito-LND, with IC50 values of 0.74 µM and 0.69 µM, respectively[1]. In H2030BrM3 cells, mito-LND suppresses the activities of mitochondrial complex I and II with IC50 values of 1.2 µM and 2.4 µM, respectively[1]. ROS production in H2030BrM3 lung cancer cells is increased by mito-LND (1 µM). In H2030BrM3 lung cancer cells, Mito-LND potently promotes mitochondrial ROS generation[1]. Mito-LND (2 µM) lowers phosphorylated AKT levels. In both the parent and metastatic lung cancer cell lines, Mito-LND also reduces the phosphorylation of P70S6K and other energy-sensing proteins, suggesting that Mito-LND directly inhibits mTOR signaling[1].
|
---|---|
ln Vivo |
Treatment with mito-LND (7.5 µmol/kg; oral gavage; 5 days per week; for 3 consecutive weeks) significantly increased potency against the progression and metastasis of lung cancer[1]. Additionally, A549 tumor xenografts develop less quickly when treated with mito-LND [1]. When NOD/SCID mice containing H2030BrM3 cells get mito-LND therapy, lung cancer brain metastases significantly decrease[1].
|
Animal Protocol |
Animal/Disease Models: Athymic nude mice (5 weeks) injected with H2030BrM3 cells[1]
Doses: 7.5 µmol/kg Route of Administration: po (oral gavage); 5 days per week; for 3 consecutive weeks Experimental Results: Dramatically diminished tumor progression. |
References |
[1]. Gang Cheng, et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019 May 17;10(1):2205.
|
Molecular Formula |
C43H45BRCL2N3OP
|
---|---|
Molecular Weight |
801.62
|
CAS # |
2361564-49-8
|
SMILES |
[Br-].ClC1C([H])=C(C([H])=C([H])C=1C([H])([H])N1C2=C([H])C([H])=C([H])C([H])=C2C(C(N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[P+](C2C([H])=C([H])C([H])=C([H])C=2[H])(C2C([H])=C([H])C([H])=C([H])C=2[H])C2C([H])=C([H])C([H])=C([H])C=2[H])=O)=N1)Cl
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : 50 mg/mL (62.37 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2475 mL | 6.2374 mL | 12.4747 mL | |
5 mM | 0.2495 mL | 1.2475 mL | 2.4949 mL | |
10 mM | 0.1247 mL | 0.6237 mL | 1.2475 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.